Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Completed · Phase 3 · Has a placebo group

Conditions studied: Adjunctive Treatment of Major Depressive Disorder

In brief

To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy

Key facts

Study ID
NCT03968159
Run by
ACADIA Pharmaceuticals Inc.
People needed
298
Starts
2019-04-25
Expected to finish
2020-05-29
Last updated by the study team
2021-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.